Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, oxaliplatin, leucovorin and
5-fluoruracil, work in different ways separately and in combination to stop tumor cells from
dividing so they stop growing or die. The use of metronomic dosing of chemotherapy minimizes
side effects and increases efficacy by anti-angiogenic effects. The pilot study demonstrated
promising responses in all patients. It is not yet known how effective this drug and dosing
combination is in treating advanced pancreatic cancer.
PURPOSE: This non-randomized phase II trial is studying giving weekly doses of paclitaxel,
oxaliplatin, leucovorin and 5-fluorouracil together as second or third-line therapy in
treating patient with locally advanced unresectable or metastatic adenocarcinoma of the
pancreas following demonstrated progression after first-line gemcitabine.